AI in diagnostics is accelerating
Roche scored an FDA Breakthrough nod for computational pathology and AI diagnostics market forecasts expect nearly fourfold growth—signaling rapid adoption of AI tools for slide prescreening and workflow automation. That combination is changing validation priorities and staffing models in cytology labs. (x.com) (manilatimes.net)
Roche’s Breakthrough Device designation came on April 29, 2025 for the VENTANA TROP2 (EPR20043) RxDx Device, identified by Roche as the first computational‑pathology companion diagnostic and built from the TROP2 algorithm, navify® image management, Roche DP‑200/DP‑600 scanners and the VENTANA TROP2 IHC assay for BenchMark ULTRA staining. (roche.com) The device is indicated as an aid to identify previously treated advanced or metastatic non‑squamous NSCLC patients without actionable genomic alterations who may benefit from datopotamab deruxtecan (DATROWAY), and Roche’s algorithm incorporates AstraZeneca’s Quantitative Continuous Scoring (QCS) platform as the computational pathology scoring backbone. (roche.com) FDA policy and programs are moving faster: the Breakthrough Devices Program offers prioritized review and enhanced FDA interaction that can accelerate premarket timelines for high‑impact diagnostics, while FDA AI/ML SaMD guidance and the 2024–2026 AI action plan emphasize lifecycle performance monitoring and total product lifecycle oversight for AI‑driven tools. (fda.gov) Market analysts projecting tool adoption peg the artificial‑intelligence‑in‑diagnostics market at roughly USD 1.77 billion in 2025, rising from an estimated USD 2.33 billion in 2026 to about USD 9.32 billion by 2031 in the Mordor Intelligence forecast cited in recent press coverage. (mordorintelligence.com) Clinical cytology precedents already exist: Hologic’s Genius Digital Diagnostics System received FDA clearance for AI‑assisted cervical cytology and pairs a volumetric imager with a Genius Cervical AI algorithm to triage and flag suspicious Pap test fields for review, a workflow prototype for slide prescreening in cytology labs. (businesswire.com) Validation and staffing consequences are concrete: CAP’s updated whole‑slide imaging validation guidance requires lab‑specific validation studies to demonstrate diagnostic equivalence before clinical use, and tools such as FDA’s ValidPath for WSI/ML performance assessment plus published studies showing AI reduces cytotechnologist screening time are driving labs to budget for WSI scanners, algorithm performance monitoring, and targeted retraining rather than simple headcount replacement. (cap.org)
